| Literature DB >> 26387944 |
Janneke G C Peeters1, Stephin J Vervoort1, Sander C Tan2, Gerdien Mijnheer3, Sytze de Roock3, Sebastiaan J Vastert3, Edward E S Nieuwenhuis4, Femke van Wijk3, Berent J Prakken3, Menno P Creyghton2, Paul J Coffer5, Michal Mokry4, Jorg van Loosdregt6.
Abstract
The underlying molecular mechanisms for many autoimmune diseases are poorly understood. Juvenile idiopathic arthritis (JIA) is an exceptionally well-suited model for studying autoimmune diseases due to its early onset and the possibility to analyze cells derived from the site of inflammation. Epigenetic profiling, utilizing primary JIA patient-derived cells, can contribute to the understanding of autoimmune diseases. With H3K27ac chromatin immunoprecipitation, we identified a disease-specific, inflammation-associated, typical enhancer and super-enhancer signature in JIA patient synovial-fluid-derived CD4(+) memory/effector T cells. RNA sequencing of autoinflammatory site-derived patient T cells revealed that BET inhibition, utilizing JQ1, inhibited immune-related super-enhancers and preferentially reduced disease-associated gene expression, including cytokine-related processes. Altogether, these results demonstrate the potential use of enhancer profiling to identify disease mediators and provide evidence for BET inhibition as a possible therapeutic approach for the treatment of autoimmune diseases.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26387944 DOI: 10.1016/j.celrep.2015.08.046
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423